174 related articles for article (PubMed ID: 26847329)
1. Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
Swisher EM; Harrell MI; Norquist BM; Walsh T; Brady M; Lee M; Hershberg R; Kalli KR; Lankes H; Konnick EQ; Pritchard CC; Monk BJ; Chan JK; Burger R; Kaufmann SH; Birrer MJ
JAMA Oncol; 2016 Mar; 2(3):370-2. PubMed ID: 26847329
[TBL] [Abstract][Full Text] [Related]
2. PPM1D Mosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations.
Pharoah PDP; Song H; Dicks E; Intermaggio MP; Harrington P; Baynes C; Alsop K; ; Bogdanova N; Cicek MS; Cunningham JM; Fridley BL; Gentry-Maharaj A; Hillemanns P; Lele S; Lester J; McGuire V; Moysich KB; Poblete S; Sieh W; Sucheston-Campbell L; Widschwendter M; ; Whittemore AS; Dörk T; Menon U; Odunsi K; Goode EL; Karlan BY; Bowtell DD; Gayther SA; Ramus SJ
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26823519
[TBL] [Abstract][Full Text] [Related]
3. Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer.
Ruark E; Snape K; Humburg P; Loveday C; Bajrami I; Brough R; Rodrigues DN; Renwick A; Seal S; Ramsay E; Duarte Sdel V; Rivas MA; Warren-Perry M; Zachariou A; Campion-Flora A; Hanks S; Murray A; Ansari Pour N; Douglas J; Gregory L; Rimmer A; Walker NM; Yang TP; Adlard JW; Barwell J; Berg J; Brady AF; Brewer C; Brice G; Chapman C; Cook J; Davidson R; Donaldson A; Douglas F; Eccles D; Evans DG; Greenhalgh L; Henderson A; Izatt L; Kumar A; Lalloo F; Miedzybrodzka Z; Morrison PJ; Paterson J; Porteous M; Rogers MT; Shanley S; Walker L; Gore M; Houlston R; Brown MA; Caufield MJ; Deloukas P; McCarthy MI; Todd JA; ; ; Turnbull C; Reis-Filho JS; Ashworth A; Antoniou AC; Lord CJ; Donnelly P; Rahman N
Nature; 2013 Jan; 493(7432):406-10. PubMed ID: 23242139
[TBL] [Abstract][Full Text] [Related]
4. Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.
Kim B; Won D; Lee ST; Choi JR
PLoS One; 2019; 14(6):e0217521. PubMed ID: 31242196
[TBL] [Abstract][Full Text] [Related]
5. PPM1D mutations in circulating white blood cells and the risk for ovarian cancer.
Akbari MR; Lepage P; Rosen B; McLaughlin J; Risch H; Minden M; Narod SA
J Natl Cancer Inst; 2014 Jan; 106(1):djt323. PubMed ID: 24262437
[TBL] [Abstract][Full Text] [Related]
6. Truncating mutations of PPM1D are found in blood DNA samples of lung cancer patients.
Zajkowicz A; Butkiewicz D; Drosik A; Giglok M; Suwiński R; Rusin M
Br J Cancer; 2015 Mar; 112(6):1114-20. PubMed ID: 25742468
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
8. Detectible mosaic truncating PPM1D mutations, age and breast cancer risk.
Machiela MJ; Myers TA; Lyons CJ; Koster R; Figg WD; Colli LM; Jessop L; Ahearn TU; Freedman ND; García-Closas M; Chanock SJ
J Hum Genet; 2019 Jun; 64(6):545-550. PubMed ID: 30850729
[TBL] [Abstract][Full Text] [Related]
9. Gain-of-function mutations of PPM1D/Wip1 impair the p53-dependent G1 checkpoint.
Kleiblova P; Shaltiel IA; Benada J; Ševčík J; Pecháčková S; Pohlreich P; Voest EE; Dundr P; Bartek J; Kleibl Z; Medema RH; Macurek L
J Cell Biol; 2013 May; 201(4):511-21. PubMed ID: 23649806
[TBL] [Abstract][Full Text] [Related]
10. Clonal Hematopoiesis-Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.
Weber-Lassalle K; Ernst C; Reuss A; Möllenhoff K; Baumann K; Jackisch C; Hauke J; Dietrich D; Borde J; Park-Simon TW; Hanker L; Prieske K; Schmidt S; Weber-Lassalle N; Pohl-Rescigno E; Kommoss S; Marmé F; Heitz F; Stingl JC; Schmutzler RK; Harter P; Hahnen E
J Natl Cancer Inst; 2022 Apr; 114(4):565-570. PubMed ID: 34963005
[TBL] [Abstract][Full Text] [Related]
11. Exome sequencing identifies somatic gain-of-function PPM1D mutations in brainstem gliomas.
Zhang L; Chen LH; Wan H; Yang R; Wang Z; Feng J; Yang S; Jones S; Wang S; Zhou W; Zhu H; Killela PJ; Zhang J; Wu Z; Li G; Hao S; Wang Y; Webb JB; Friedman HS; Friedman AH; McLendon RE; He Y; Reitman ZJ; Bigner DD; Yan H
Nat Genet; 2014 Jul; 46(7):726-30. PubMed ID: 24880341
[TBL] [Abstract][Full Text] [Related]
12. Uterine lavage identifies cancer mutations and increased
Ghezelayagh TS; Kohrn BF; Fredrickson J; Manhardt E; Radke MR; Katz R; Gray HJ; Urban RR; Pennington KP; Liao JB; Doll KM; Simons EJ; Burzawa JK; Goff BA; Speiser P; Swisher EM; Norquist BM; Risques RA
Cancer Res Commun; 2022 Oct; 2(10):1282-1292. PubMed ID: 36311816
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations.
Jean S; Li J; Katsaros D; Wubbenhorst B; Maxwell KN; Fishbein L; McLane MW; Benedetto C; Canuto EM; Mitra N; Zhang L; Nathanson KL; Tanyi JL
Oncotarget; 2016 Jul; 7(30):48577-48585. PubMed ID: 27191893
[TBL] [Abstract][Full Text] [Related]
14. PPM1D is a potential therapeutic target in ovarian clear cell carcinomas.
Tan DS; Lambros MB; Rayter S; Natrajan R; Vatcheva R; Gao Q; Marchiò C; Geyer FC; Savage K; Parry S; Fenwick K; Tamber N; Mackay A; Dexter T; Jameson C; McCluggage WG; Williams A; Graham A; Faratian D; El-Bahrawy M; Paige AJ; Gabra H; Gore ME; Zvelebil M; Lord CJ; Kaye SB; Ashworth A; Reis-Filho JS
Clin Cancer Res; 2009 Apr; 15(7):2269-80. PubMed ID: 19293255
[TBL] [Abstract][Full Text] [Related]
15. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of C-terminal truncated PPM1D enhances the effect of doxorubicin on cell viability in human colorectal carcinoma cell line.
Kozakai Y; Kamada R; Kiyota Y; Yoshimura F; Tanino K; Sakaguchi K
Bioorg Med Chem Lett; 2014 Dec; 24(24):5593-5596. PubMed ID: 25466181
[TBL] [Abstract][Full Text] [Related]
17. Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.
Krimmel JD; Schmitt MW; Harrell MI; Agnew KJ; Kennedy SR; Emond MJ; Loeb LA; Swisher EM; Risques RA
Proc Natl Acad Sci U S A; 2016 May; 113(21):6005-10. PubMed ID: 27152024
[TBL] [Abstract][Full Text] [Related]
18. Contribution of de novo and mosaic
Renaux-Petel M; Charbonnier F; Théry JC; Fermey P; Lienard G; Bou J; Coutant S; Vezain M; Kasper E; Fourneaux S; Manase S; Blanluet M; Leheup B; Mansuy L; Champigneulle J; Chappé C; Longy M; Sévenet N; Paillerets BB; Guerrini-Rousseau L; Brugières L; Caron O; Sabourin JC; Tournier I; Baert-Desurmont S; Frébourg T; Bougeard G
J Med Genet; 2018 Mar; 55(3):173-180. PubMed ID: 29070607
[TBL] [Abstract][Full Text] [Related]
19. Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
Krimmel-Morrison JD; Ghezelayagh TS; Lian S; Zhang Y; Fredrickson J; Nachmanson D; Baker KT; Radke MR; Hun E; Norquist BM; Emond MJ; Swisher EM; Risques RA
Gynecol Oncol; 2020 Feb; 156(2):407-414. PubMed ID: 31839337
[TBL] [Abstract][Full Text] [Related]
20. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
